| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Oct―17 |
Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome |
M.M. Said, A.M. Braam, E. Duijvelaar, J.R. Schippers, L. Atmowihardjo, J. Twisk, H.J. Bogaard, E.L. Swart, J. Aman, I.H. Bartelink |
| 2 |
[GO] |
2025―Oct―07 |
SARS-CoV-2 N7-Methyltransferase Inhibitors: Towards Selective and Potent Antivirals |
Katarina Sujova, Vladimir Frecer |
| 3 |
[GO] |
2025―Jan―16 |
The impact of community pharmacies on equity in access to professional rapid antigen testing for SARS-CoV-2 in Portugal |
José Guerreiro, Sónia Romano, Inês Teixeira, Klára Dimitrovová, Rúben Pereira, António Teixeira Rodrigues, Ema Paulino |
| 4 |
[GO] |
2024―Mar―11 |
Distribution and suitability of pulmonary surfactants as a vehicle for topically applied antibodies in healthy and SARS-CoV-2 infected rodent lungs. |
Lea-Adriana Barlang, Isabelle Deimel, Björn-Patrick Mohl, Claudia Blaurock, Anne Balkema-Buschmann, Kristina Weinbender, Brian Hess, Helena Obernolte, Olivia M. Merkel, Andreas Popp |
| 5 |
[GO] |
2023―Dec―14 |
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2 |
Fabiola Guareschi, Elena Del Favero, Caterina Ricci, Laura Canté, Martina Brandolini, Vittorio Sambri, Sara Nicoli, Silvia Pescina, Davide D'Angelo, Irene Rossi, Francesca Buttini, Ruggero Bettini, Fabio Sonvico |
| 6 |
[GO] |
2023―Sep―30 |
A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects |
Xin-Mei Yang, Yang Yang, Bu-Fan Yao, Pan-Pan Ye, Yan Xu, Shao-Ping Peng, Yu-Mei Yang, Pan Shu, Pei-Jin Li, Shan Li, Hong-Lin Hu, Qian Li, Lin-Lin Song, Ke-Guang Chen, Hai-Yan Zhou, Ye-Hui Zhang, Fu-Rong Zhao, Bo-Hao Tang, Wei Zhang, Xin-Fang Zhang, Shu-Meng Fu, Guo-Xiang Hao, Yi Zheng, Jing-Shan Shen, Ye-Chun Xu, Xiang-Rui Jiang, Lei-Ke Zhang, Ren-Hong Tang, Wei Zhao |
| 7 |
[GO] |
2023―Jul―23 |
Population pharmacokinetic modeling and simulation for nirmatrelvir exposure assessment in Chinese older patients with COVID-19 infection |
Yuchen Qu, Cunjin Su, Zheng Xiang, Yueyuan Wang, Junping Han, Jie Pan, Zhu Shen |
| 8 |
[GO] |
2023―Jun―11 |
AEROSOLIZED SULFATED HYALURONAN DERIVATIVES PROLONG THE SURVIVAL OF K18 ACE2 MICE INFECTED WITH A LETHAL DOSE OF SARS-COV-2 |
Mauro Pavan, Chiara D. Fanti, Alba Di Lucia, Elena Canato, Laura Acquasaliente, Fabio Sonvico, Jennifer Delgado, Amberlee Hicks, Jordi B. Torrelles, Viraj Kulkarni, Varun Dwivedi, Anna M. Zanellato, Devis Galesso, Gianfranco Pasut, Francesca Buttini, Luis Martinez-Sobrido, Cristian Guarise |
| 9 |
[GO] |
2023―Mar―02 |
Pharmacokinetics and Pharmacodynamics of Imatinib for Optimal Drug Repurposing from Cancer to COVID-19 |
Nadia Baalbaki, Erik Duijvelaar, Medhat M. Said, Job Schippers, Pierre M. Bet, Jos Twisk, Sarah Fritchley, Cristina Longo, Kazien Mahmoud, Anke H. Maitland- van der Zee, Harm Jan Bogaard, Eleonora L. Swart, Jurjan Aman, Imke H. Bartelink |
| 10 |
[GO] |
2022―Nov―30 |
The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells |
Mohammed A.A. Saleh, Makoto Hirasawa, Ming Sun, Berfin Gülave, Jeroen Elassaiss-Schaap, Elizabeth C.M. de Lange |
| 11 |
[GO] |
2021―Sep―17 |
Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors |
Suyash Pant, N.R. Jena |
| 12 |
[GO] |
2021―Mar―26 |
In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2) |
Sagar Barge, Dhananjay Jade, Gokul Gosavi, Narayan Chandra Talukdar, Jagat Borah |
| 13 |
[GO] |
2021―Feb―21 |
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach |
Yiming Zhang, Rory A Greer, Yuwei Song, Hrithik Praveen, Yuhua Song |
| 14 |
[GO] |
2021―Feb―02 |
Importance of Glutamine 189 flexibility in SARS-CoV-2 main protease: lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics |
Mohamed A. Said, Amgad Albohy, Mohamed A Abdelrahman, Hany S. Ibrahim |
| 15 |
[GO] |
2020―Oct―25 |
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial |
Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu, Qingwei Zhao, Tingbo Liang, Yunqing Qiu |
| 16 |
[GO] |
2020―Sep―30 |
Therapeutic Strategies for SARS-CoV-2 acting on ACE-2 |
A. Vitiello, F. Ferrara |
| 17 |
[GO] |
2020―Aug―20 |
Emerging strategies on in silico drug development against COVID-19: challenges and opportunities |
Manisha Yadav, Swasti Dhagat, J. Satya Eswari |
| 18 |
[GO] |
2020―Jul―28 |
Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages |
Natesh Singh, Etienne Decroly, Abdel-Majid Khatib, Bruno O. Villoutreix |
| 19 |
[GO] |
2020―Jul―12 |
A Molecular Docking Study Repurposes FDA Approved Iron Oxide Nanoparticles to Treat and Control COVID-19 Infection |
Yasmin Abo-zeid, Nasser.S. Ismail, Gary.R. McLean, Nadia.M. Hamdy |
| 20 |
[GO] |
2020―May―23 |
Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics |
Sajjad Ahmad, Afifa Navid, Rabia Farid, Ghulam Abbas, Faisal Ahmad, Naila Zaman, Nousheen Parvaiz, Syed Sikander Azam |
| 21 |
[GO] |
2020―May―14 |
High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19 |
Rupal Ojha, Nidhi Gupta, Biswajit Naik, Satyendra Singh, Vijay Kumar Verma, Dhaneswar Prusty, Vijay Kumar Prajapati |
|
